Sun Pharma Advanced Research Co Complete Financial Statements
In FY2026, Sun Pharma Advanced Research Co (SPARC) reported revenue ₹15 Cr, net profit ₹1,761 Cr and EPS ₹54.27, with a net profit margin of 11740.0% and ROE of 131.5%. Full financial statements from FY2023 to FY2026 (4 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. Review SPARC earnings multiple to evaluate earnings-based valuation against sector peers.
Complete Financial Data Export
Profitability Ratios
Balance Sheet Ratios
SPARC Revenue, Net Profit & EBITDA — Year-on-Year Growth
SPARC YoY (Mar 2025 vs Mar 2026) — revenue -44.4%, net profit +3035.0%, EBITDA -22.6%. For live price, earnings ratios and company overview, see Sun Pharma Advanced Research C stock price NSE.
SPARC Income Statement — Revenue, EBITDA & Net Profit
Sun Pharma Advanced Research Co revenue ₹15 Cr, EBITDA ₹-65 Cr, net profit ₹1,761 Cr, EPS ₹54.27 (2026) — net profit margin 11740.0%. Explore SPARC fundamental worth to estimate fundamental worth using multiple valuation models.
| Particulars | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | Mar 2024 | Jun 2024 | Dec 2024 | Sept 2023 | Mar 2023 | Jun 2023 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15 | 8 | 27 | 19 | 8 | 13 | 21 | 18 | 15 | 30 | 58 | 34 | 20 |
| Expenses | 80 | 74 | 80 | 62 | 77 | 116 | 122 | 110 | 89 | 113 | 137 | 126 | 117 |
| EBITDA | -65 | -66 | -53 | -43 | -69 | -103 | -101 | -92 | -74 | -83 | -79 | -92 | -96 |
| Operating Profit Margin % | -506.00% | -836.00% | -196.00% | -540.00% | -817.00% | -800.00% | -639.00% | -555.00% | -494.00% | -432.00% | -188.00% | -427.00% | -740.00% |
| Depreciation | 2 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Interest | 12 | 8 | 5 | 6 | 9 | 1 | 1 | 1 | 3 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1,761 | -76 | -61 | -52 | -80 | -107 | -105 | -96 | -79 | -86 | -82 | -95 | -100 |
| Tax | 0 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 1,761 | -76 | -60 | -52 | -80 | -107 | -106 | -96 | -80 | -86 | -82 | -95 | -100 |
| Earnings Per Share (₹) | 54.27 | -2.34 | -1.84 | -1.60 | -2.48 | -3.31 | -3.26 | -2.96 | -2.45 | -2.66 | -2.55 | -2.94 | -3.07 |
SPARC Balance Sheet — Assets, Liabilities & Shareholders' Equity
SPARC total assets ₹2,171 Cr, total equity ₹1,339 Cr, total liabilities ₹ Cr (2026) — ROE 131.5%.
| Particulars | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| Total Assets | 2,171 | 336 | 515 | 830 |
| Current Assets | 1,862 | 26 | 269 | 455 |
| Fixed Assets | 157 | 99 | 108 | 106 |
| Capital Work in Progress | 1 | 54 | 44 | 27 |
| Investments | 0 | 0 | 2 | 291 |
| Other Assets | 0 | 183 | 362 | 407 |
| LIABILITIES | ||||
| Total Liabilities | ||||
| Current Liabilities | 78 | 178 | 124 | 138 |
| Non-Current Liabilities | ||||
| SHAREHOLDERS' EQUITY | ||||
| Total Equity | 1,339 | -217 | 126 | 513 |
| Share Capital | 33 | 33 | 33 | 33 |
| Reserves & Surplus | 1,306 | -249 | 93 | 480 |
SPARC Cash Flow Statement — Operating, Investing & Financing
Sun Pharma Advanced Research Co operating cash flow ₹-360 Cr, investing ₹158 Cr, financing ₹199 Cr, net cash flow ₹-3 Cr (2025).
| Particulars | March 2025 | March 2024 | March 2023 |
|---|---|---|---|
| Operating Activities | -360 | -429 | -69 |
| Investing Activities | 158 | 392 | -548 |
| Financing Activities | 199 | 42 | 617 |
| Net Cash Flow | -3 | 5 | -1 |